The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

OBJECTIVE: Taspoglutide is a long-acting glucagon-like peptide 1 receptor agonist developed for treatment of type 2 diabetes. The efficacy and safety of once-weekly taspoglutide was compared with twice-daily exenatide. RESEARCH DESIGN AND METHODS: Overweight adults with inadequately controlled type...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Balas, Bogdan, Charbonnel, Bernard, Bolli, Geremia B., Boldrin, Mark, Ratner, Robert, Balena, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579343/
https://www.ncbi.nlm.nih.gov/pubmed/23139373
http://dx.doi.org/10.2337/dc12-0709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579343/
https://www.ncbi.nlm.nih.gov/pubmed/23139373
http://dx.doi.org/10.2337/dc12-0709

Ejemplares similares